APOBEC3B and melanoma: The survival of melanoma cells under of ATRi (VE-821/VE-822) or Chk1i (Rabusertib) treatment was significantly improved by A3B depletion, indicating an essential role of A3B in conferring sensitivity to these drugs (Fig. 5E–H).